(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome ...

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for ... people treated with CagriSema achieved a weight loss of 15.7% after 68 weeks compared to 3.1% ...

CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Novo Nordisk has ended its partnership with Hims & Hers Health. Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

CHICAGO — CagriSema, a new weekly injection from Novo Nordisk combining the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide, significantly reduced weight and improved ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...